Effect of infant immunisation with meningococcus serogroup C-CRM(197) conjugate vaccine on diphtheria immunity and reactogenicity in pre-school aged children.
The majority of Men C conjugate vaccines given in the UK use CRM(197), a mutant diphtheria toxoid, as their protein carrier. We studied the effects of prior immunisation with Men C-CRM(197) conjugate vaccine on immunity to diphtheria in 193 children before and after a booster dose of Men C at 4 years. Baseline diphtheria antibodies were higher in children given four previous doses of Men C (P<0.0001) and tended to be higher following boosting in those who had received three or four doses. This enhanced immunity was not associated with increased reactogenicity.
McVernon
Jodie
J
Department of Paediatrics, Level 4, John Radcliffe Hospital, Headley Way, Headington, Oxon OX20 1XN, UK. jodie.mcvernon@paediatrics.ox.ac.uk
MacLennan
Jenny
J
Clutterbuck
Elizabeth
E
Buttery
Jim
J
Moxon
E Richard
ER
D002675:Child, Preschool; D004165:Diphtheria / Q000276:immunology* / Q000517:prevention & control; D004168:Diphtheria Toxoid / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D008589:Meningococcal Infections / Q000276:immunology* / Q000517:prevention & control; D022401:Meningococcal Vaccines / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D015203:Reproducibility of Results; D013997:Time Factors; D018074:Vaccines, Conjugate / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*
D004168:Diphtheria Toxoid; D022401:Meningococcal Vaccines; D018074:Vaccines, Conjugate